Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials

• Published in: BMC pharmacology & toxicology 2019-11, Vol.20 (1), p.72-72, Article 72
• Main Authors: Huang, Cheng-Zhi, Jiang, Zhi-Hui, Wang, Jian, Luo, Yue, Peng, Hua
• Format: Article
• Language: English
• Subjects: Allergic diseases; Allergy; Analysis; Anesthesia; Antihistamines; Asthma; Bias; Clinical trials; Cognition - drug effects; Cognitive ability; Collaboration; Dermatitis; Drug dosages; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - etiology; Drugs; Fexofenadine; Histamine H1 Antagonists, Non-Sedating - adverse effects; Histamine H1 Antagonists, Non-Sedating - pharmacology; Humans; Hypersensitivity; Information processing; Meta-analysis; Occupational safety; Psychomotor Performance - drug effects; Quality of life; Randomization; Randomized controlled trial; Randomized Controlled Trials as Topic; Safety; Studies; Systematic review; Terfenadine - adverse effects; Terfenadine - analogs & derivatives; Terfenadine - pharmacology; Workers
• ISSN: 2050-6511; 2050-6511
• DOI: 10.1186/s40360-019-0363-1

As a new generation antihistamine, fexofenadine has been widely used in allergic diseases. However, there is still a lack of collective evidence regarding the antihistamine effects and safety profiles of fexofenadine relative to other antihistamine drugs and placebo. Therefore, we aimed to systematically evaluate the antihistamine effects and safety of fexofenadine. An electronic literature search of randomized controlled trials (RCTs) was performed using Embase, Cochrane and PubMed from establishment to January 1st, 2018. RCTs comparing the antihistamine effects or safety (adverse events, sedative effects, and cognitive/psychomotor function) of fexofenadine with either other antihistamines or placebo for healthy subjects and patients with allergy were selected. Fifty-one studies of 14,551 participants met the inclusion criteria. When compared with the first-generation antihistamines, fexofenadine produced significantly lower adverse events frequency (OR = 0.446; 95% CI: 0.214 to 0.929, P = 0.031), significantly lower sedative effects frequency (OR = 0.265; 95% CI: 0.072 to 0.976, P = 0.046) and significantly less change of all cognitive/psychomotor function. When compared with the second-generation antihistamines, fexofenadine produced significantly marginal sedative effects (OR = 0.59; 95% CI, 0.38 to 0.93; P = 0.02) and significantly less change of most of the cognitive/psychomotor function. When compared with placebo, fexofenadine produced more significant antihistamine effects. Fexofenadine has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. Fexofenadine probably has a favorable safety profile, which is more likely better than that of the first-generation antihistamines. There is lack of data to support that fexofenadine has a better overall safety profile compared to the second-generation antihistamines, however, some presently available evidence on sedative effects and certain aspects of cognitive/psychomotor function favors fexofenadine. Therefore, fexofenadine may be worthy of recommendation for safety related workers.